Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Golden Cross macht sich bereit: 1.350 Goldabbaustellen, 55 Ladder-Ziele und ein historischer Volltreffer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A403XM | ISIN: US09057N4097 | Ticker-Symbol: IBP0
Berlin
22.02.24 | 21:52
0,340 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIO-PATH HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
BIO-PATH HOLDINGS INC 5-Tage-Chart

Aktuelle News zur BIO-PATH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.08.BIO-PATH HOLDINGS, INC. - 8-K, Current Report5
11.07.NSE - BIO-PATH HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities2
24.06.Bio-Path Holdings kündigt Rücktritte von Führungskräften und Betriebspause an1
24.06.BIO-PATH HOLDINGS, INC. - 8-K, Current Report1
09.06.Bio-Path Holdings, Inc.: Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum1
03.06.Bio-Path Holdings, Inc.: Bio-Path Holdings Provides Clinical and Operational Update158HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
► Artikel lesen
15.05.BIO-PATH HOLDINGS, INC. - 10-Q, Quarterly Report1
BIO-PATH Aktie jetzt für 0€ handeln
01.05.Bio-Path Holdings, Inc.: Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients128HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
► Artikel lesen
29.04.BIO-PATH HOLDINGS, INC. - 8-K, Current Report1
28.03.Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Full Year 2024 Financial Results179HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
► Artikel lesen
18.03.Bio-Path Holdings, Inc.: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients122HOUSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
► Artikel lesen
27.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.02.20253.142The following instruments on Boerse Frankfurt do have their last trading day on 27.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.02.2025ISIN NameCA15748D1069 CHAKANA...
► Artikel lesen
13.02.Bio-Path Holdings, Inc.: Bio-Path Holdings Expands Global Patent Portfolio170HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
► Artikel lesen
13.02.Bio-Path Holdings, Inc.: Bio-Path Holdings Provides Key Clinical Updates214First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase...
► Artikel lesen
12.02.Bio-Path Holdings, Inc.: Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia140Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12...
► Artikel lesen
10.01.Bio-Path Holdings, Inc.: Bio-Path Holdings Provides 2025 Clinical and Operational Update262Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path...
► Artikel lesen
19.12.24Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology1.061CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over...
► Artikel lesen
19.12.24Bio-Path Holdings, Inc.: Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity148HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
► Artikel lesen
11.12.24Bio-Path Holdings, Inc.: Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients183Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic Program and Discontinues Enrollment...
► Artikel lesen
15.11.24Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results245Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1